ZyVersa Therapeutics Inc. (ZVSA)
0.60
0.01 (2.13%)
At close: Apr 02, 2025, 3:58 PM
0.61
1.90%
After-hours: Apr 02, 2025, 07:50 PM EDT
Company Description
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.
It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases.
ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
ZyVersa Therapeutics Inc.
| Country | United States |
| IPO Date | Feb 11, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Stephen C. Glover |
Contact Details
Address: 2200 N. Commerce Parkway Weston, Florida United States | |
| Website | https://www.zyversa.com |
Stock Details
| Ticker Symbol | ZVSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001859007 |
| CUSIP Number | 98987D201 |
| ISIN Number | US98987D2018 |
| Employer ID | 86-2685744 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen C. Glover | Co-Founder, Chairman, Chief Executive Officer & President |
| Peter Wolfe | Chief Financial Officer & Secretary |
| Dr. Pablo A. Guzman FACC, M.D. | Chief Medical Officer, Senior Vice President of Medical Affairs & Chairman of Renal Scientific Advisory Board |
| Karen A. Cashmere | Chief Commercial Officer |
| Melda Uzbil O'connell | Senior Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 07, 2025 | 8-K | Current Report |
| Jan 24, 2025 | S-8 | Filing |
| Jan 17, 2025 | DEF 14A | Filing |
| Dec 30, 2024 | 424B3 | Filing |
| Dec 20, 2024 | S-3 | Filing |
| Dec 20, 2024 | PRE 14A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |